EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Subscribe To Our Newsletter & Stay Updated
